Detail Information of Exogenous Modulation

General Information of Drug Transporter (DT)
DT ID DTD0023 Transporter Info
Gene Name SLC22A5
Transporter Name Organic cation/carnitine transporter 2
Gene ID
6584
UniProt ID
O76082
Exogenous factors (drugs, dietary constituents, etc.) Modulation of This DT (EGM)

Approved Drug

  Cefepime

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefepime inhibits the transportation of L-carnitine by SLC22A5 (IC50 = 1700 microM) [1]

Affected Drug/Substrate

 L-carnitine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-OCTN2

  DT Modulation 2

 Cefepime inhibits the activity of SLC22A5 [1]

  Nicotine polacrilex

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Nicotine inhibits the transportation of L-Carnitine by SLC22A5 [2]

Affected Drug/Substrate

 L-Carnitine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN2

  DT Modulation 2

 Nicotine inhibits the transportation of Tetraethylammonium by SLC22A5 [4]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-OCTN2

  L-carnitine

            2 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 L-carnitine inhibits the transportation of L-Carnitine by SLC22A5 [3]

Affected Drug/Substrate

 L-Carnitine Modulation Type Inhibition

Cell System

 Oocytes-OCTN2

  DT Modulation 2

 L-carnitine inhibits the transportation of Carnitine by SLC22A5 [5]

Affected Drug/Substrate

 Carnitine Modulation Type Inhibition

  Cefoselis

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefoselis inhibits the transportation of L-carnitine by SLC22A5 (IC50 = 6400 microM) [1]

Affected Drug/Substrate

 L-carnitine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-OCTN2

  Emetine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Emetine inhibits the transportation of L-carnitine by SLC22A5 (IC50 = 4.2 microM) [6]

Affected Drug/Substrate

 L-carnitine Modulation Type Inhibition

Cell System

 Oocytes-OCTN2

  Linagliptin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Linagliptin inhibits the transportation of Ergothioneine by SLC22A5 [7]

Affected Drug/Substrate

 Ergothioneine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN2

  Quinine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quinine inhibits the transportation of Ergothioneine by SLC22A5 [7]

Affected Drug/Substrate

 Ergothioneine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN2

  Aldosterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Aldosterone inhibits the transportation of L-Carnitine by SLC22A5 [2]

Affected Drug/Substrate

 L-Carnitine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN2

  Cefsulodin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cefsulodin inhibits the transportation of L-Carnitine by SLC22A5 [2]

Affected Drug/Substrate

 L-Carnitine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN2

  Lomefloxacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Lomefloxacin inhibits the transportation of L-Carnitine by SLC22A5 [2]

Affected Drug/Substrate

 L-Carnitine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN2

  Ofloxacin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ofloxacin inhibits the transportation of L-Carnitine by SLC22A5 [2]

Affected Drug/Substrate

 L-Carnitine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN2

  Pyrilamide

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Pyrilamide inhibits the transportation of L-Carnitine by SLC22A5 [2]

Affected Drug/Substrate

 L-Carnitine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN2

  Valproic Acid

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Valproic Acid inhibits the transportation of L-Carnitine by SLC22A5 [2]

Affected Drug/Substrate

 L-Carnitine Modulation Type Inhibition

Cell System

 Human embryonic kidney 293 cells (HEK293)-OCTN2

  Methamphetamine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Methamphetamine inhibits the transportation of Tetraethylammonium by SLC22A5 [4]

Affected Drug/Substrate

 Tetraethylammonium Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-OCTN2

  Carbamazepine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Carbamazepine increases the expression of SLC22A5 [8]

Regulation Mechanism

 via enhancement of Nuclear receptor subfamily 1 group I member 2 (NR1I2) Transcription Factor Info

Cell System

 Human liver samples

  Cisplatin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cisplatin inhibits the expression of SLC22A5 [9]

Regulation Mechanism

 via the inhibition of Peroxisome proliferator-activated receptor alpha (PPARA) Transcription Factor Info

Cell System

 FVB wild-type mice

  Raloxifene Hydrochloride

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Raloxifene Hydrochloride affects the expression of SLC22A5 [10]

  Verapamil

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Verapamil inhibits the activity of SLC22A5 [11]

  Cyclosporine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cyclosporine increases the expression of SLC22A5 [12]

  Tretinoin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tretinoin increases the expression of SLC22A5 [13]

  Zidovudine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Zidovudine increases the expression of SLC22A5 [14]

  Rosiglitazone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Rosiglitazone increases the expression of SLC22A5 [15]

  Vorinostat

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Vorinostat inhibits the expression of SLC22A5 [16]

  Decitabine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Decitabine increases the expression of SLC22A5 [17]

  Urethane

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Urethane inhibits the expression of SLC22A5 [18]

  Doxorubicin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Doxorubicin inhibits the expression of SLC22A5 [19]

  Arsenic

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Arsenic affects the expression of SLC22A5 [20]

  Sunitinib

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Sunitinib inhibits the expression of SLC22A5 [21]

  Estradiol

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Estradiol increases the expression of SLC22A5 [22]

  Progesterone

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Progesterone inhibits the activity of SLC22A5 [23]

Drug in Phase 2 Trial

  Genistein

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Genistein increases the expression of SLC22A5 [26]

Drug in Phase 1 Trial

  Quercetin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Quercetin inhibits the expression of SLC22A5 [24]

Drug Withdrawn

  Cephaloridine

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Cephaloridine inhibits the transportation of L-carnitine by SLC22A5 (IC50 = 230 microM) [1]

Affected Drug/Substrate

 L-carnitine Modulation Type Inhibition

Cell System

 Human cervical cancer cell line (Hela)-OCTN2

Natural Product

  Tobacco Smoke Pollution

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Tobacco Smoke Pollution affects the expression of SLC22A5 [28]

Environmental toxicant

  Polychlorinated dibenzodioxin

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Polychlorinated dibenzodioxin affects the expression of SLC22A5 [25]

Carcinogen

  Ethyl Methanesulfonate

            1 DT Activity Modulations Related to This Exogenous Factor Click to Show/Hide the Full List

  DT Modulation 1

 Ethyl Methanesulfonate increases the expression of SLC22A5 [27]
References
1 beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem. 2000 Jan 21;275(3):1699-707.
2 Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84.
3 Molecular identification of a novel carnitine transporter specific to human testis. Insights into the mechanism of carnitine recognition. J Biol Chem. 2002 Sep 27;277(39):36262-71.
4 cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun. 1998 May 29;246(3):589-95.
5 Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-increasing agent. Drug Metab Dispos. 2011 Jun;39(6):1088-96.
6 Functional and pharmacological characterization of human Na(+)-carnitine cotransporter hOCTN2. Am J Physiol Renal Physiol. 2000 Sep;279(3):F584-91.
7 Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. Drug Metab Dispos. 2013 Jan;41(1):149-58.
8 Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006 Nov;80(5):440-456.
9 Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin Cancer Res. 2010 Oct 1;16(19):4789-99.
10 Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Mol Biol Cell. 2004 Mar;15(3):1262-72.
11 Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. Drug Metab Dispos. 2005 Jan;33(1):31-7.
12 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
13 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
14 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23.
15 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
16 Definition of transcriptome-based indices for quantitative characterization of chemically disturbed stem cell development: introduction of the STOP-Toxukn and STOP-Toxukk tests. Arch Toxicol. 2017 Feb;91(2):839-864.
17 Multiple drug transporters mediate the placental transport of sulpiride. Arch Toxicol. 2017 Dec;91(12):3873-3884.
18 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
19 Bringing in vitro analysis closer to in vivo: Studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
20 Inorganic Arsenic as an Endocrine Disruptor: Modulation of the Glucocorticoid Receptor Pathway in Placental Cells via CpG Methylation. Chem Res Toxicol. 2019 Mar 18;32(3):493-499.
21 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761.
22 17 beta-Estradiol Activates HSF1 via MAPK Signaling in ER alpha-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533.
23 Maternal Plasma l-Carnitine Reduction During Pregnancy Is Mainly Attributed to OCTN2-Mediated Placental Uptake and Does Not Result in Maternal Hepatic Fatty Acid -Oxidation Decline. Drug Metab Dispos. 2019 Jun;47(6):582-591.
24 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
25 Identification of novel low-dose bisphenol a targets in human foreskin fibroblast cells derived from hypospadias patients. PLoS One. 2012;7(5):e36711.
26 Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
27 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
28 Assessment of the impact of aerosol from a potential modified risk tobacco product compared with cigarette smoke on human organotypic oral epithelial cultures under different exposure regimens. Food Chem Toxicol. 2018 May;115:148-169.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.